Skip to main content

Day: April 1, 2021

Robert Ziegler Joins the Solutions 30 Management Board as Chief Transformation Officer

Solutions 30 announces the arrival of Robert Ziegler as Chief Transformation Officer, member of the Management Board. His appointment, with immediate effect, was approved by the Supervisory Board of Solutions 30. Robert Ziegler will be tasked with accelerating the transformation and the structuring of the organization in line with its growth ambition. Robert Ziegler spent 18 years at AT Kearney. During this period, he was involved in several large-scale infrastructure projects in the transport and logistics sector, before becoming Partner and Managing Director in charge of the European infrastructure and transport portfolio. He also founded AT Kearney’s Middle East office in Dubai, where he spent five years building a very successful business and contributing to the development of infrastructure in the GCC Region. He then joined DHL International...

Continue reading

ROBERT ZIEGLER REJOINT LE DIRECTOIRE DE SOLUTIONS 30, EN QUALITE DE CHIEF TRANSFORMATION OFFICER

Solutions 30 annonce l’arrivée de Robert Ziegler en qualité de Chief Transformation Officer, membre du Directoire. Sa nomination, avec effet immédiat, a été approuvée par le Conseil de Surveillance du Groupe. Robert Ziegler aura pour mission d’accélérer la mutation et la structuration du Groupe en cohérence avec ses ambitions de croissance. Robert Ziegler a passé 18 ans chez AT Kearney. Au cours de cette période, il a participé à plusieurs projets d’envergure dans les infrastructures de transport et logistique, avant de devenir Associé et Managing Director en charge de la practice Infrastructures et Transport au niveau européen. Il a également fondé le bureau d’AT Kearney pour le Moyen-Orient à Dubaï, où il a passé cinq ans et construit une activité qui a contribué au développement des infrastructures dans la région. Il rejoint...

Continue reading

Basilea announces closing of previously announced transaction regarding divestment of its Chinese R&D subsidiary

Basel, Switzerland, April 01, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced the successful closing of the previously announced divestment of its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”) to the U.S.-based custom manufacturing organization PHT International Inc. (“PHT”) for a total consideration of USD 6.3 million. Basilea has received the initial payment of USD 2.5 million and is entitled to receive additional payments of USD 3.8 million over the course of the next three years. All 72 employees of BPC and the facilities have been transferred to PHT. PHT continues to provide R&D services to Basilea through the existing site in China. About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed...

Continue reading

Basilea gibt Abschluss der zuvor angekündigten Transaktion zur Veräusserung ihres chinesischen F&E-Tochterunternehmens bekannt

Basel, 01. April 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute den erfolgreichen Abschluss der zuvor angekündigten Veräusserung ihres chinesischen Forschungs- und Entwicklungs- (F&E) Tochterunternehmens Basilea Pharmaceutica China Ltd. („BPC“) an das US-amerikanische Custom-Manufacturing-Unternehmen PHT International Inc. („PHT“) für einen Gesamtbetrag von USD 6.3 Mio. bekannt. Basilea hat die initiale Zahlung von USD 2.5 Mio. erhalten und im Laufe der nächsten drei Jahre Anspruch auf weitere Zahlungen in Höhe von USD 3.8 Mio. Alle 72 Mitarbeitende von BPC sowie die gesamten Gebäude und Anlagen wurden von PHT übernommen. PHT stellt Basilea auch zukünftig F&E-Dienstleistungen über den bestehenden Standort in China zur Verfügung. Über Basilea Basilea ist ein im Jahr 2000 mit Hauptsitz in der Schweiz gegründetes biopharmazeutisches...

Continue reading

Celyad Oncology Announces April 2021 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, April 01, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in April 2021: Cell & Gene Meeting on the MediterraneanDates: April 6-9, 2021Panel Title: Alternative Cell Solutions for OncologyPanel Participant: Filippo Petti, CEOPanel Webcast: Available on-demand through the conference website starting Thursday, April 8Company Presentation: Available on-demand through the conference website starting Tuesday, April 6 2021 Virtual Wells Fargo Biotech Corporate Access DayDate: Thursday, April 8, 2021 Kempen & Co. Life Sciences Conference – European...

Continue reading

AS Ekspress Grupp: Audited annual report 2020

The Supervisory Board of AS Ekspress Grupp approved the annual report 2020. The financial results for 2020 remain unchanged compared to the preliminary disclosure on 19th February 2021. In 2020, the consolidated audited sales revenue of AS Ekspress Grupp totalled EUR 63.2 million that is 6% lower compared to 2019. Group’s consolidated audited net profit for 2020 totalled EUR 2.54 million, increasing by 80%. AS Eskpress Grupp audited annual report for 2020 is attached to this stock exchange realease and made available on AS Ekspress Grupp website egrupp.ee For the first time, AS Ekspress Grupp has prepared a separate interactive online annual report, which can be found at: 2020-annual-report.egrupp.ee. As well as company information and a financial section, the online report offers many extra features, including videos and additional web...

Continue reading

AS Ekspress Grupp: Auditeeritud majandusaasta aruanne 2020

ASi Ekspress Grupp nõukogu kinnitas 2020. aasta majandusaasta aruande. 2020. aasta finantstulemused ei ole võrreldes 19. veebruaril 2021 avaldatud esialgsete tulemustega muutunud. ASi Ekspress Grupp 2020. majandusaasta konsolideeritud auditeeritud müügitulu oli 63,2 miljonit eurot, mis kahanes 6% võrreldes 2019. aastaga. Kontserni 2020. majandusaasta konsolideeritud auditeeritud puhaskasum oli 2,54 miljonit eurot kasvades 80%.   ASi Ekspress Grupp auditeeritud 2020. aasta majandusaasta aruanne on lisatud käesolevale teatele ning on kättesaadav ASi Ekspress Grupp koduleheküljel egrupp.ee Esmakordselt on AS Ekspress Grupp koostanud eraldi interarktiivse online aastaaruande, mis asub aadressil: 2020-annual-report.egrupp.ee. Lisaks informatsioonile ettevõtte kohta ja finantsadmetele sisaldab online aruanne täiendavat funktsionaalsust, sh...

Continue reading

Sodexo First Half Fiscal 2021 Results: rebound in profitability and strong free cashflow

Sodexo First Half Fiscal 2021 Results: rebound in profitability and strong free cashflowImproving organic revenue trend quarter by quarter, at -21.7% for H1 Underlying operating profit margin at 3.1%, large beat on assumptions Exceptional free cashflow generation for a first half Assumptions:H2 organic revenue growth between +10 and +15% H2 Underlying operating profit margin at around 3.1% at constant rate Cash conversion more than 100% for the full yearIssy-les-Moulineaux, April 1, 2021 – Sodexo (NYSE Euronext Paris FR 0000121220-OTC: SDXAY). At the Board of Directors meeting held on March 31, 2021 and chaired by Sophie Bellon, the Board closed the Consolidated accounts for the First half Fiscal 2021 ended February 28, 2021. Financial performance for First half Fiscal 2021(in millions of euro) H1 FISCAL 2021 H1 FISCAL...

Continue reading

Sodexo : rebond de la profitabilité et niveau élevé de liquidités générées par les opérations au 1er semestre de l’exercice 2020-2021

Sodexo : rebond de la profitabilité et niveau élevé de liquidités générées par les opérations au 1ersemestre de l’exercice 2020-2021Amélioration de la croissance interne du chiffre d’affaires de trimestre en trimestre, à – 21,7 % pour le 1er semestre Marge d’exploitation de 3,1 %, largement supérieure aux hypothèses Niveau exceptionnel de liquidités générées par les opérations pour un 1er semestre Hypothèses :croissance interne du chiffre d’affaires pour le 2nd semestre entre + 10 à + 15 % marge d’exploitation pour le 2nd semestre d’environ 3,1 % à taux constant cash conversion1 pour l’exercice supérieure à 100 %Issy-les-Moulineaux, le 1eravril 2021 – Sodexo (NYSE Euronext Paris FR 0000121220-OTC: SDXAY). Lors de la réunion du Conseil d’Administration du 31 mars 2021, présidée par Sophie Bellon, le Conseil a...

Continue reading

Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders

Allschwil, Switzerland – April 1, 2021 Idorsia Ltd (SIX: IDIA) today issued the formal Notice to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Business Report of the year ending December 31, 2020 will be held on Wednesday May 12, 2021. The meeting will be held in accordance with the requirements of the COVID 19 Ordinance 2, issued by the Swiss Federal Council. As a result, attendance in person will not be possible and voting will take place by independent proxy only. Mathieu Simon, Chairman of the Board of Directors commented:“Once again, we must prioritize the health of our shareholders and the Idorsia team, so we are unable to host our shareholders at an in-person meeting. I trust that our engaged shareholder base will make their voice heard none-the-less through...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.